What you’ll be able to do:
- Use BIO One-on-One Partnering to request and schedule virtual meetings with your preferred method (teleconference, video meeting service, or another medium), any day, any time—and continue messaging with potential partners through mid-July.
- Attend live and on-demand educational panels focused on topics including COVID-19, infectious diseases, vaccine development, digital health, business development, and the latest therapeutic advancements in biotech.
- Watch presentations from companies across the industry, either during BIO Digital or after, on your own time.
And we’re offering new, reduced pricing—starting at just $950 for BIO members, to maximize participation.
This does not replace the convention—but it does help amplify the work we’re already doing to facilitate virtual collaboration.
Because now, more than ever, we need industry partnerships—like just-announced expanded partnership between BIO members Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. on groundbreaking RNAi antiviral therapeutics to treat COVID-19, as just one of the many examples.
Jim’s Judgment: The coronavirus is an urgent focus for the biotechnology industry as we work tirelessly to combat this public health threat. Now, more than ever, it’s critical for the biotechnology world to convene and forge collaborations, partnerships and research to advance innovations for our patients and to solve our most timely global issues. Especially now, we see how these connections can make a lifesaving difference. We look forward to seeing you—online—in June. – BIO President & CEO Jim Greenwood
Register for BIO Digital 2020 at www.bio.org/events/bio-digital.
Follow the convention@BIOConvention and join the conversation @IAmBIOtech.
P.S. Save the date! The BIO International Convention will return June 14-17, 2021, in Boston, where we’ll hopefully get to celebrate incredible progress in treating and preventing the coronavirus.
More News:
Biopharma Dive: Amgen, partnering with Seattle's Adaptive, begins coronavirus drug search
“Adaptive will screen immune proteins from patients who've recovered from COVID-19, searching for antibodies active against SARS-Cov-2 that Amgen can then engineer and make into a drug.”
MedicalCountermeasures.gov: BARDA, Department of Defense, and SAb Biotherapeutics to partner to develop a novel COVID-19 therapeutic
“The therapeutic, called SAB-185, is part of a new class of immunotherapies that relies on SAb’s platform technology to produce fully human polyclonal antibodies as the basis for the drug. This technology produces the antibodies without the need for blood donations from people who have recovered from the virus; this approach produces greater quantities of the drug than the traditional human antibody donor methods.”
POLITICO: The fight over unproven drugs for coronavirus
“The Food and Drug Administration’s rush to greenlight unproven malaria medicines to fight the coronavirus may derail clinical trials of other potential cures for the deadly virus.”
STAT: Big biotech venture funds raise billions despite coronavirus fears
“It would hardly seem to be time for investors to put money to work. Yet two of the sector’s largest venture capital firms—ARCH Venture Partners and Flagship Pioneering—say that is exactly what they plan to do.”
